ライフサイエンスコーパス: obstructive lung disease

1 t poor periodontal health is associated with obstructive lung disease.

2 uity between diagnosis of asthma and chronic obstructive lung disease.

3 igands may improve beta-agonist treatment of obstructive lung disease.

4 n lungs with chronic cigarette smoke-induced obstructive lung disease.

5 teria from the Global Initiative for Chronic Obstructive Lung Disease.

6 L-18 were also seen in patients with chronic obstructive lung disease.

7 hages from smokers and patients with chronic obstructive lung disease.

8 triggers exacerbations of asthma and chronic obstructive lung disease.

9 sepsis, asthma, cystic fibrosis, and chronic obstructive lung disease.

10 the ventilatory mechanics of a patient with obstructive lung disease.

11 samples obtained from patients with chronic obstructive lung disease.

12 tility of FVC/TLC in identifying features of obstructive lung disease.

13 ibutable to heart failure and 12% to chronic obstructive lung disease.

14 ls with preexisting heart failure or chronic obstructive lung disease.

15 ent related to the severity of the patient's obstructive lung disease.

16 n people with cystic fibrosis is due to muco-obstructive lung disease.

17 such as hypertension, diabetes, and chronic obstructive lung disease.

18 seline lung function in SLTX recipients with obstructive lung disease.

19 ing of B(2)AR actions favorable for treating obstructive lung disease.

20 nary embolism, pneumonia, heart failure, and obstructive lung disease.

21 n was used to assess HIV as a determinant of obstructive lung disease.

22 onounced for restrictive impairment than for obstructive lung disease.

23 as yet to help patients with CF or any other obstructive lung disease.

24 n traits and identified a candidate gene for obstructive lung disease.

25 both in healthy volunteers and patients with obstructive lung disease.

26 ulation mediates the pathogenesis of chronic obstructive lung diseases.

27 ted therapeutic targets in the management of obstructive lung diseases.

28 e front-line treatments for asthma and other obstructive lung diseases.

29 bstructive pulmonary disease (COPD) are muco-obstructive lung diseases.

30 l airways obstruction is a common feature of obstructive lung diseases.

31 atic, "tethered" mucus layer in chronic muco-obstructive lung diseases.

32 cal management in CF and, potentially, other obstructive lung diseases.

33 ems that could participate in CC16's role in obstructive lung diseases.

34 has been described as a serum biomarker for obstructive lung diseases.

35 in the development of therapeutics to treat obstructive lung diseases.

36 cessation of transport in persons with muco-obstructive lung diseases.

37 s impaired in cystic fibrosis (CF) and other obstructive lung diseases.

38 a novel approach to managing bronchospasm in obstructive lung diseases.

39 l/yr for GOLD (Global Initiative for Chronic Obstructive Lung Disease) 0-4 was as follows: 41.8 (47.7

40 TRS for COPD (Global Initiative for Chronic Obstructive Lung Disease 2-4), prospective FEV(1) change

41 The GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2020 Report aims to provide a

42 we observed 117 acute hospitalizations with obstructive lung disease, 227 acute hospitalizations wit

43 sorder, obstructive sleep apnea, and chronic obstructive lung disease (adjusted hazard ratio, 0.93, 9

44 ndromes, bronchiolitis, and cryptic cases of obstructive lung disease among United States citizens, s

45 rug that has long been used to treat chronic obstructive lung disease and acetaminophen toxicity and

46 ely increased in postviral mice with chronic obstructive lung disease and in humans with very severe

47 is the greatest risk factor for both chronic obstructive lung disease and interstitial lung disease.

48 dysplasia (BPD) is characterized by lifelong obstructive lung disease and profound, refractory bronch

49 is review, we first introduce representative obstructive lung diseases and examine limitations of cur

50 ory lung diseases, including asthma, chronic obstructive lung disease, and cystic fibrosis, which cau

51 respiratory diseases such as asthma, chronic obstructive lung disease, and cystic fibrosis.

52 pulmonary research and clinical practice in obstructive lung disease, and drug discovery platforms w

53 acute respiratory distress syndrome, chronic obstructive lung disease, and idiopathic pulmonary fibro

54 s in infants, exacerbations in patients with obstructive lung disease, and life-threatening pneumonia

55 l diagnoses of eosinophilic lung disease and obstructive lung disease, and marked eosinophilia in spu

56 s in infants, exacerbations in patients with obstructive lung disease, and pneumonia in immunocomprom

57 more likely to develop preoperative chronic obstructive lung disease, and postoperative pulmonary hy

58 r smokers, with well-controlled asthma, mild obstructive lung disease, and relatively high neutrophil

59 ease in particle deposition in patients with obstructive lung disease, and this can be an important f

60 ease, heart failure, stroke, asthma, chronic obstructive lung disease, and type 2 diabetes mellitus.

61 % CI, 1.12-3.56]), asthma (including chronic obstructive lung disease; AOR, 1.40 [95% CI, 1.06-1.85])

62 Mortality rates of obstructive lung disease are starting to stabilize among

63 Muco-obstructive lung diseases are typically associated with

64 life (Short Form-36 [SF-36]), hypertension, obstructive lung disease, arthralgias, and peripheral ne

65 tube placement was seen in those with severe obstructive lung disease, as measured by percentage of p

66 f obstructive lung disease, the phenotype of obstructive lung disease associated with work-related or

67 the first line drugs in the treatment of the obstructive lung diseases asthma and chronic obstructive

68 ption and progression of the two most common obstructive lung diseases (asthma and chronic obstructiv

69 t the ATP11A and DPP9 loci, and with chronic obstructive lung diseases at the NPNT locus.

70 and lung volumes in 29 patients with chronic obstructive lung disease before lung-volume-reduction su

71 % in the open-repair group died from chronic obstructive lung disease; between-group difference, -2.8

72 ting in the first follow-up of the Burden of Obstructive Lung Disease (BOLD) cohort study in Sweden,

73 ctive pulmonary disease (COPD) are prevalent obstructive lung diseases, both of which are characteriz

74 isease categories (restrictive lung disease, obstructive lung disease, bronchiectasis) were labelled

75 , compared to five of fifteen without severe obstructive lung disease, but this difference was not si

76 y duration, 5 yr) and the Canadian Cohort of Obstructive Lung Disease (CanCOLD) study (n = 1,551 subj

77 es data from the prospective Canadian Cohort Obstructive Lung Disease (CanCOLD) study, examining CT i

78 ugh August 31, 2022; and the Canadian Cohort Obstructive Lung Disease (CanCOLD), which enrolled 1561

79 sites, 2010-2018) and the Canadian Cohort of Obstructive Lung Disease (CanCOLD), which involved 1272

80 rtant disease (Global Initiative for Chronic Obstructive Lung Disease classification B-D), 16.4% had

81 cording to the Global Initiative for Chronic Obstructive Lung Disease classification system (P = .001

82 cording to the Global Initiative for Chronic Obstructive Lung Disease classification system (P = .001

83 international Global Initiative for Chronic Obstructive Lung Disease COPD strategy document, with th

84 Chronic obstructive lung disease (COPD) and diffuse parenchymal

85 Asthma and chronic obstructive lung disease (COPD) are both inflammatory co

86 , normal smokers, smokers with early chronic obstructive lung disease (COPD), and smokers with establ

87 obstructive lung diseases asthma and chronic obstructive lung disease (COPD).

88 ic liver disease, viral hepatitis, overdose, obstructive lung disease, coronary artery disease, and p

89 with the 2017 Global Initiative for Chronic Obstructive Lung Disease criteria.

90 met the GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria for COPD with quantit

91 position compared to supine in patients with obstructive lung disease, decreasing from 0.264+/-0.024

92 Patients with obstructive lung diseases display abnormal circadian rhy

93 predicted) and Global Initiative for Chronic Obstructive Lung Disease E status (at least two moderate

94 mechanism, which is noxiously upregulated in obstructive lung diseases (e.g. chronic obstructive pulm

95 Patients with chronic obstructive lung disease experience an increased risk of

96 ds among people who died with a diagnosis of obstructive lung disease from 1979 through 1993, using d

97 s from four of the five subjects with severe obstructive lung disease gave a positive response to GRP

98 ingen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) study.

99 den Universities study of Corticosteroids in Obstructive Lung Disease (GLUCOLD; n = 89).

100 LV(EV) between Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1 and GOLD 4 COPD was re

101 tion, 224 with Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1 COPD, and 200 with GOL

102 er-smokers and Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1-2 and GOLD 3-4 patient

103 d Spirometry), Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1-2 COPD, and GOLD 3-4 C

104 rkers in 3,698 Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1-4 patients and 3,479 c

105 art disease or stage 2 Global initiative for Obstructive Lung Disease (GOLD) COPD who had been clinic

106 pirometry according to Global Initiative for Obstructive Lung Disease (GOLD) criteria).

107 mined by using Global initiative for chronic Obstructive Lung Disease (GOLD) criteria.

108 defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criterion (FEV(1)/FVC <

109 (n = 116) with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade U (unclassified) o

110 for those with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades C-D (n = 558), 98

111 ssociation for Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A and group B pati

112 ince 2001, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strate

113 ne patients in Global Initiative for Chronic Obstructive Lung Disease (GOLD) II, 85 in GOLD III, and

114 life, and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) proposes a predisease st

115 The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Science Committee used e

116 terised by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric category (1-

117 stratified by Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage (GOLD 0, no COPD;

118 ly between the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 0 and preserved ra

119 atients with a Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2 lung index.

120 ollows: having Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 3 or 4 disease at

121 COPD (n = 10); Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I (n = 6), II (n =

122 Patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV COPD had increa

123 sed to predict Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage.

124 categorized by Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 1-4 (ppFEV(1) of

125 nts to predict Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages was compared usin

126 combined with Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging, patients with G

127 Current Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy recommends the

128 The new Global Initiative for Obstructive Lung Disease (GOLD) stratification of chroni

129 nale: According to the Global Initiative for Obstructive Lung Disease (GOLD), the FEV(1)/FVC ratio is

130 mmended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

131 nd Prevotella (Global Initiative for Chronic Obstructive Lung Disease [GOLD] A and B) before transiti

132 sed with mild (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 1) COPD.

133 nts with COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 4) and 28 samples

134 ery severe COPD (Global Health Initiative on Obstructive Lung Disease [GOLD] Stage IV) compared with

135 m smokers with Global Initiative for Chronic Obstructive Lung Disease grade 2-4 COPD enrolled in two

136 nts with GOLD [Global Initiative for Chronic Obstructive Lung Disease] grade 1B COPD, 11 age-matched

137 Based on Global Initiative for Chronic Obstructive Lung Disease guidelines, 461 patients (17.6%

138 Knowledge of genetic origins of obstructive lung diseases has made inhaled gene therapy

139 h pulmonary disease, particularly those with obstructive lung disease, have a high rate of panic symp

140 ta-agonists), in widespread clinical use for obstructive lung disease, have been associated with an i

141 chronic conditions, including frequent pain, obstructive lung disease, heart disease, diabetes, and p

142 d to second-hand smoke in the workplace, and obstructive lung disease history.

143 5% confidence interval, 3.39-12.2) for acute obstructive lung disease hospitalizations, 2.03 (1.43-2.

144 onfidence interval [CI], 1.12-2.10), chronic obstructive lung disease (HR, 1.56; CI, 1.15-2.10), fema

145 e COPD (n = 5, Global Initiative for Chronic Obstructive Lung Disease I or II), emphysema without air

146 cedents, 2,554,959 (8.2%) had a diagnosis of obstructive lung disease (ICD-9 490 to 493.9, 496) liste

147 nts with COPD (Global Initiative for Chronic Obstructive Lung Disease II-IV) who were carefully chara

148 y severe COPD (Global Initiative for Chronic Obstructive Lung Disease III/IV) compared with both smok

149 Prevalence of obstructive lung disease in 544 HIV-infected and 529 HIV

150 mild restrictive pattern in DL-S and severe obstructive lung disease in DL-OBS.

151 e delivery of aerosolised bronchodilators in obstructive lung disease in general.

152 high prevalence of respiratory symptoms and obstructive lung disease in HIV-infected subjects, the p

153 tis (DPB), an important cause of progressive obstructive lung disease in the Far East, represents a d

154 prevention of Pneumocystis colonization and obstructive lung disease in the SHIV model.

155 of the increased risk and manifestations of obstructive lung diseases in HIV-infected patients and s

156 major pathophysiological hallmarks of severe obstructive lung diseases including chronic obstructive

157 Chronic obstructive lung disease is characterized by persistent

158 Obstructive lung disease is the most common form of resp

159 We conclude that mortality related to obstructive lung disease is under-estimated in studies t

160 Data are from the Inhaled Steroids in Obstructive Lung Disease (ISOLDE) trial.

161 54,959 decedents, only 1,106,614 (43.3%) had obstructive lung disease listed as the underlying cause

162 The findings support that chronic obstructive lung diseases may have at least part of thei

163 tterns in eight patients with severe chronic obstructive lung disease (median FEV1 = 0.79 L, range 0.

164 ngs from individuals with a spectrum of muco-obstructive lung diseases (MOLDs) or COVID-19 identified

165 .58; 95% confidence interval, 1.14-2.19) and obstructive lung disease (multivariable-adjusted odds ra

166 adenovirus bronchiolitis or pneumonia, fixed obstructive lung disease on pulmonary function testing,

167 did not have heart disease, stroke, chronic obstructive lung disease, or cancer at the time they ans

168 flammatory disease, transplantation, chronic obstructive lung disease, other cancers, and hypopituita

169 Association of OSA with chronic obstructive lung disease (overlap syndrome) and morbid o

170 act on the development of asthma and chronic obstructive lung disease phenotypes, and that there are

171 ed into phenotypes of prematurity-associated obstructive lung disease (POLD, Forced expiratory volume

172 using spirometry, as prematurity-associated obstructive lung disease (POLD; FEV(1) < lower limit of

173 nal analysis of the CanCOLD (Canadian Cohort Obstructive Lung Disease) population-based study.

174 alysis showed an effect modification whereby obstructive lung disease prevalence among persons with l

175 The unadjusted obstructive lung disease prevalence was similar in HIV-i

176 lines from the Global Initiative for Chronic Obstructive Lung Disease reorganised treatment objective

177 ive for Asthma/Global Initiative for Chronic Obstructive Lung Disease report, to provide health profe

178 in 2016) completed a questionnaire regarding obstructive lung diseases, respiratory symptoms, potenti

179 by using the composite Global Initiative for Obstructive Lung Disease scale (P < .0001).

180 Many patients with chronic obstructive lung disease show increased airways responsi

181 ants (11%) met Global Initiative for Chronic Obstructive Lung Disease spirometric criteria for lung-f

182 in current and former Global Initiative for Obstructive Lung Disease stage 0 smokers predicted struc

183 a for COPD (defined as Global Initiative for Obstructive Lung Disease stage 0).

184 ilder disease (Global Initiative for Chronic Obstructive Lung Disease stage 0-2 obstruction in 732 of

185 dy), or (GOLD [Global Initiative for Chronic Obstructive Lung Disease Stage 0-2).

186 test effect in Global Initiative for Chronic Obstructive Lung Disease stage 1, where each exacerbatio

187 re observed in Global Initiative for Chronic Obstructive Lung Disease stage 2 and 3 subjects.

188 nts with COPD (Global Initiative for Chronic Obstructive Lung Disease stage 2) was negatively associa

189 10% smaller in Global Initiative for Chronic Obstructive Lung Disease stage 4 versus stage 1 COPD (P

190 d according to Global Initiative for Chronic Obstructive Lung Disease stage higher than 1 (odds ratio

191 subjects with Global Initiative for Chronic Obstructive Lung Disease stage I COPD and 20 healthy sub

192 nts with COPD (Global Initiative for Chronic Obstructive Lung Disease stage I to II) before and after

193 patients with Global Initiative for Chronic Obstructive Lung Disease stage I-IV COPD, and smoking an

194 nfection in 17 Global Initiative for Chronic Obstructive Lung Disease stage II subjects with COPD and

195 patients with Global Initiative for Chronic Obstructive Lung Disease stage II-IV COPD and persistent

196 COPD that was Global Initiative for Chronic Obstructive Lung Disease stage II-IV were enrolled.

197 nts with COPD (Global Initiative for Chronic Obstructive Lung Disease stage II-IV) underwent hyperpol

198 gnosis of COPD Global Initiative for Chronic Obstructive Lung Disease stage II-IV.

199 s performed on Global Initiative for Chronic Obstructive Lung Disease stage IV COPD lungs with TLOs.M

200 age and milder Global Initiative for Chronic Obstructive Lung Disease stage were associated with bett

201 ema, increased Global Initiative for Chronic Obstructive Lung Disease stage, and COPD disease status.

202 ed with higher Global Initiative for Chronic Obstructive Lung Disease stage, and correlated negativel

203 es of patient age, the Global Initiative for Obstructive Lung Disease stage, or number of PR sessions

204 cise index, or Global Initiative for Chronic Obstructive Lung Disease stage.

205 ects with COPD Global Initiative for Chronic Obstructive Lung Disease stages 0 to 4 and 73 nonsmokers

206 articipants at Global Initiative for Chronic Obstructive Lung Disease stages 0, 1, and 2, respectivel

207 severity (ie, Global Initiative for Chronic Obstructive Lung Disease stages 0-4), Pi10 increased (4.

208 nt wheeze, and Global Initiative for Chronic Obstructive Lung Disease stages 2 and higher chronic obs

209 d >/=40 years, Global Initiative for Chronic Obstructive Lung Disease stages III-IV, and one or more

210 nts and milder Global Initiative for Chronic Obstructive Lung Disease stages.

211 ] years, GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages I-IV: 9.4, 42.5, 37.5,

212 s based on the Global Initiative for Chronic Obstructive Lung Disease staging criteria were adjusted

213 conference symposium titled "Depression and Obstructive Lung Disease: State of the Science and Futur

214 Endpoints), and GenKOLS (Genetics of Chronic Obstructive Lung Disease) studies were analyzed.

215 The Burden of Obstructive Lung Disease study is a multinational cross-

216 mages were obtained from the Canadian Cohort Obstructive Lung Disease study visit 1 from 2009 to 2013

217 als enrolled in the CanCOLD (Canadian Cohort Obstructive Lung Disease) study with linked ambient fine

218 articipating in the CanCOLD (Canadian Cohort Obstructive Lung Disease) study, with at least 12 months

219 e lungs, are closely associated with chronic obstructive lung diseases such as chronic bronchitis and

220 al infection of the airways is a hallmark of obstructive lung diseases such as cystic fibrosis (CF),

221 Applications in patients with obstructive lung diseases, such as asthma and chronic ob

222 eful technique for image-guided treatment of obstructive lung diseases, such as bronchial thermoplast

223 risk model's variables included sex, chronic obstructive lung disease, symptom duration, neutrophil c

224 iolitis obliterans is a rare form of chronic obstructive lung disease that follows a severe insult to

225 ) is a prominent feature of asthma and other obstructive lung diseases that is minimally affected by

226 hypertension, diabetes mellitus, or chronic obstructive lung disease), the age-adjusted hazard ratio

227 es contribute to a significant proportion of obstructive lung disease, the phenotype of obstructive l

228 for efficacious bronchodilators for treating obstructive lung diseases, this pathway can be exploited

229 ld smoking may predispose neonates with muco-obstructive lung disease to bacterial exacerbations.

230 previously established mouse model of severe obstructive lung diseases, to produce lower-mortality bu

231 significant decrease in Rrs in patients with obstructive lung disease was also observed.

232 Death from chronic obstructive lung disease was just over 50% more common w

233 Emphysema and chronic obstructive lung disease were previously identified as m

234 tory failure (end-tidal CO2 of 75 mm Hg) and obstructive lung disease were simulated in a double-cham

235 Its manifestations include obstructive lung disease, which can be severe and for wh

236 outh demonstrated decreased reversibility of obstructive lung disease, which is atypical of asthma.

237 he longitudinal Tucson Epidemiology Study of Obstructive Lung Disease who had at least one DL(CO) mea

238 disease (COPD) are highly prevalent chronic obstructive lung diseases with an associated high burden